SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Stefan N. Constantinescu, Emilie Leroy, Vitalina Gryshkova, Christian Pecquet, Alexandra Dusa, Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers, Biochemical Society Transactions, 2013, 41, 4, 1048

    CrossRef

  2. 2
    Karoline Gäbler, Iris Behrmann, Claude Haan, JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms, JAK-STAT, 2013, 2, 3, e25025

    CrossRef

  3. 3
    Lori N. Griner, Kathy L. McGraw, Joseph O. Johnson, Alan F. List, Gary W. Reuther, JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth, British Journal of Haematology, 2013, 160, 2
  4. 4
    Kavitha Gnanasambandan, Andrew T. Magis, Peter P. Sayeski, A shift in the salt bridge interaction of residues D620 and E621 mediates the constitutive activation of Jak2-H538Q/K539L, Molecular and Cellular Biochemistry, 2012, 367, 1-2, 125

    CrossRef

  5. 5
    Shunzhou Wan, Peter V. Coveney, Regulation of JAK2 Activation by Janus Homology 2: Evidence from Molecular Dynamics Simulations, Journal of Chemical Information and Modeling, 2012, 52, 11, 2992

    CrossRef

  6. 6
    Andrew J. Brooks, Michael J. Waters, The growth hormone receptor: mechanism of activation and clinical implications, Nature Reviews Endocrinology, 2010, 6, 9, 515

    CrossRef

  7. 7
    Geoff M. Gordon, Que T. Lambert, Kenyon G. Daniel, Gary W. Reuther, Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ, Biochemical Journal, 2010, 432, 2, 255

    CrossRef